FDMT News and Press, 4D Molecular Therapeutics Inc.

2026-03-06 13:46:01 ET 4D Molecular Therapeutics, Inc. (FDMT) TD Cowen 46th Annual Health Care Conference March 3, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: 4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Hea...

Aptevo Therapeutics Inc. (APVO) is expected to report $-8.09 for Q4 2025 Longeveron Inc. (LGVN) is expected to report $-0.41 for Q4 2025 Genesco Inc. (GCO) is expected to report $3.73 for Q4 2026 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.04 for Q4 2025 N...

Sunstone Hotel Investors Inc. (SHO) is expected to report $0.18 for Q4 2025 GT Biopharma Inc. (GTBP) is expected to report $-0.22 for Q4 2025 Global Partners LP representing Limited Partner Interests (GLP) is expected to report $0.6 for Q4 2025 4D Molecular Therapeutics Inc. (FDMT) is...

2026-02-26 17:38:44 ET 4D Molecular Therapeutics, Inc. (FDMT) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 2.35%. The average open to low on the day of earnings was -4.12%. The averag...

2026-02-26 17:33:44 ET 4D Molecular Therapeutics, Inc. (FDMT) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in FDMT stock price following earnings has averaged ±1.14% , with a median of...

Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections  4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patie...

2026-01-14 13:35:58 ET 4D Molecular Therapeutics, Inc. (FDMT) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: 4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Mo...

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 2026 4D-150 PRISM wet AMD 2-year Phase 2b data expected mid-2026 4D-150 DME ...

2025-12-19 09:00:00 ET Investment Overview - Update Since My Last Note On 4D-150 The last time I updated on the Emeryville, California-based genetic medicine specialist 4D Molecular Therapeutics ( FDMT ) it was early October 2024, and I made a bull case for the company's sto...

2025-12-17 14:02:38 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AER...